TLDR: The global generative AI in healthcare market is set for substantial expansion, driven by increasing administrative burdens, significant funding, and continuous advancements in AI/ML technologies. Valued at approximately $3.3 billion in 2025, the market is forecast to surge to $39.8 billion by 2035, exhibiting a robust Compound Annual Growth Rate (CAGR) of 28%. This transformative technology is expected to revolutionize patient care, drug discovery, diagnostics, and administrative efficiencies, offering billions in potential savings.
DUBLIN – The global healthcare sector is on the cusp of a major transformation with the rapid adoption of generative artificial intelligence (AI), according to recent market research reports from ResearchAndMarkets.com. The ‘Generative AI in Healthcare Market: Industry Trends and Global Forecasts to 2035’ report highlights a market currently valued at an estimated USD 3.3 billion in 2025. This figure is projected to skyrocket to USD 39.8 billion by 2035, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 28% over the forecast period. Other reports indicate slightly different, but equally optimistic, figures, with one valuing the market at USD 2.79 billion in 2025, reaching over USD 50.92 billion by 2035, at a CAGR of 33.7%.
This significant growth is primarily fueled by several critical factors: the escalating administrative burden faced by healthcare professionals, a surge in funding and investments into AI/ML advancements, and the inherent capabilities of generative AI to produce data-driven outputs such as insights, images, and videos.
The healthcare industry is grappling with numerous challenges, including inefficient clinical workflows, rising treatment costs, persistent staff shortages, and widespread burnout among healthcare workers. A Medscape report from 2024 revealed that nearly 49% of physicians experience burnout, with administrative tasks accounting for 62% of this burden and long working hours for 41%. Furthermore, traditional drug discovery methods are notoriously time-intensive and often lack a focus on personalized treatment, with approximately 90% of drug candidates failing to reach advanced clinical trial phases despite substantial investments.
Generative AI offers promising solutions to these entrenched problems. Its implementation in administrative tasks alone could generate annual savings of approximately USD 150 billion across the healthcare sector. Studies also suggest that generative AI could reduce diagnostic errors by up to 85% and decrease nursing overtime by 21%, potentially saving nearly USD 469,000 over three years per hospital.
From an application perspective, the market is segmented into drug discovery and development, diagnosis, treatment, administrative tasks, and other areas. The treatment segment currently leads the generative AI in healthcare market and is expected to maintain its dominance, driven by the technology’s ability to boost treatment efficacy and patient care while reducing administrative burdens. The diagnosis segment is anticipated to be the fastest-growing, with an annualized rate of 29.8% during the forecast period.
In terms of offerings, the technology/platform segment holds a significant market share, close to 75% in 2025, and is projected to continue its strong growth. End-users of generative AI in healthcare include healthcare providers, pharmaceutical and life sciences companies, and healthcare payers. Healthcare providers are expected to capture the largest revenue share, around 55% in 2025, while pharmaceutical and life sciences companies are anticipated to be the fastest-growing segment.
Also Read:
- Generative AI Revolutionizes Genome Editing, Surpassing Natural Protein Design
- Generative AI Reshaping North American Software Development Lifecycle with Agentic Workflows and Robust Governance by 2025
Geographically, North America dominated the market in 2024 with a 40.8% revenue share, attributed to robust investments in digital health infrastructure, early AI adoption, and supportive regulatory frameworks. The region is projected to grow at a CAGR of 21.3% from 2025 to 2032. Meanwhile, the Asia-Pacific market is poised for the fastest growth, with a CAGR of 24.0% from 2025 to 2032, driven by increasing healthcare digitalization in countries like China, Japan, and India, rising medical tourism, and expanding government funding for AI in healthcare. China, in particular, led the Asia-Pacific market with an 8.9% share of global revenue in 2024, propelled by vast healthcare demand and rapid AI adoption.
